[REVISION HISTORY]

FDA, Japan, and China approve Orzeyful for narcolepsy

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-24 13:31 UTC → 2026-09-10 11:14 UTC · added ~~removed~~

~~FDA~~ FDA, Japan, and ~~Japanese approval of~~ China approve Orzeyful for narcolepsy

The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton), the first oral orexin-2 receptor agonist for adults with narcolepsy type 1. Unlike previous treatments that manage symptoms, Orzeyful targets the underlying biological loss of orexin signaling to regulate sleep and wake cycles. Clinical trials involving 273 patients demonstrated that the medication significantly improved wakefulness and reduced symptoms such as cataplexy, sleep paralysis, and hallucinations. Reported side effects include insomnia, increased saliva production, and urinary urgency or frequency. Following the approval, the Drug Enforcement Administration (DEA) is reviewing the drug to assess its potential for addiction. Takeda’s leadership anticipates the medication will receive a schedule IV designation, suggesting a low potential for abuse. Expanding its regulatory footprint, Takeda announced that the Japanese Ministry of Health, Labour and Welfare has also approved Orzeyful for treating narcolepsy type 1 in adults. As a first-in-class oral orexin receptor 2 agonist, it is the only medicine in Japan indicated to treat the disease holistically. The drug was originally discovered in Takeda’s laboratories in Japan, and the company is preparing for its domestic launch. Orzeyful has since received further regulatory approval in China from the National Medical Products Administration. In China, the therapy is approved for use in adults and adolescents aged 16 and older.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.